Pfizer breakthrough: New immunotherapy combo slashes bladder cancer recurrence risk by 32%

Discover how Pfizer’s new sasanlimab combination therapy is redefining treatment for high-risk bladder cancer after 30 years — read the breakthrough results now! Read More